- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | VITRAFY LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| So | VITRAFY LIFE SCIENCES LIMITED: Notification regarding unquoted securities - VFY | - | ASX | ||
| 21.11. | VITRAFY LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 21.11. | VITRAFY LIFE SCIENCES LIMITED: Notification of cessation of securities - VFY | 2 | ASX | ||
| VITRAFY LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.11. | VITRAFY LIFE SCIENCES LIMITED: Final Director's Interest Notices | - | ASX | ||
| 20.11. | VITRAFY LIFE SCIENCES LIMITED: Application for quotation of securities - VFY | - | ASX | ||
| 20.11. | VITRAFY LIFE SCIENCES LIMITED: Results of 2025 Annual General Meeting | - | ASX | ||
| 20.11. | VITRAFY LIFE SCIENCES LIMITED: 2025 Annual General Meeting Chair Address & Presentation | 1 | ASX | ||
| 19.11. | VITRAFY LIFE SCIENCES LIMITED: Bell Potter Healthcare Conference Presentation | - | ASX | ||
| 07.11. | VITRAFY LIFE SCIENCES LIMITED: Release of Securities from Mandatory Escrow | - | ASX | ||
| 24.10. | ASX Quarterly Health Wrap: Lumos lands US$317m deal as ReNerve and Vitrafy hit key milestones | 1 | Stockhead | ||
| 23.10. | Vitrafy Life Sciences Q1 FY26 slides: VCU2 delivery milestone as commercialization accelerates | 2 | Investing.com | ||
| 22.10. | VITRAFY LIFE SCIENCES LIMITED: Quarterly Investor Briefing Presentation | - | ASX | ||
| 21.10. | VITRAFY LIFE SCIENCES LIMITED: Q1 FY26 Quarterly Activities Report and Appendix 4C | - | ASX | ||
| 20.10. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy Q1 FY26 Investor Briefing | 1 | ASX | ||
| 16.10. | VITRAFY LIFE SCIENCES LIMITED: 2025 Notice of Annual General Meeting | - | ASX | ||
| 15.10. | VITRAFY LIFE SCIENCES LIMITED: Board Renewal | - | ASX | ||
| 15.10. | VITRAFY LIFE SCIENCES LIMITED: Initial Director's Interest Notice | - | ASX | ||
| 08.10. | Vitrafy Q3 FY2025 presentation: $34M liquidity supports 2025 product launch timeline | 2 | Investing.com | ||
| 06.10. | VITRAFY LIFE SCIENCES LIMITED: Managing Director and CEO Remuneration Update | - | ASX |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 4,775 | +13,69 % | Recursion jumps as J.P. Morgan upgrades on lead program | ||
| QIAGEN | 38,480 | +1,29 % | QIAGEN NV steht still - für mich ist das kein Stillstand! | ||
| IMMUNOME | 20,570 | -12,06 % | Immunome-Aktie fällt nach Ankündigung einer Kapitalerhöhung über 400 Mio. US-Dollar | ||
| AVIDITY BIOSCIENCES | 71,87 | -0,14 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| KYVERNA THERAPEUTICS | 7,100 | -30,73 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock | EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) ("Kyverna"), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients... ► Artikel lesen | |
| BIONTECH | 78,15 | -0,45 % | Erfreuliche Studiendaten verleihen der BioNTech-Aktie wieder Rückenwind, doch für einen Durchbruch reicht es noch nicht | Vor fünf Jahren dominierte die Aktie von BioNTech noch das Börsengeschehen, mittlerweile schafft das Papier es aber nur noch selten auf das Radar der Anleger. Das Geschäft mit Corona-Impfstoffen ist... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 61,08 | -0,97 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 267,15 | -2,78 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 32,720 | -4,47 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| KYMERA THERAPEUTICS | 81,33 | -3,32 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| VOR BIOPHARMA | 14,310 | -9,72 % | Vor Biopharma: TD Cowen startet mit Kaufempfehlung und verweist auf Telitacicept-Potenzial | ||
| MINERALYS THERAPEUTICS | 37,540 | +4,25 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,970 | +0,02 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| IMMUNOVANT | 26,770 | +0,53 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| SUMMIT THERAPEUTICS | 17,200 | -0,17 % | Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development |
Das Unternehmen VITRAFY LIFE SCIENCES LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITRAFY LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.